Metabolic intervention with GLP-1 or its biologically active analygues to improve the function of the ischemic and reperfused brain

Abstract

It has now been discovered that GLP-1 treatment after acute stroke or hemorrhage, preferably intravenous administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and maintaining euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.

Description

field of invention [0001] The present invention relates to an effective treatment for improving ischemic and reperfused brain function. Background of the invention [0002] A stroke, or cerebrovascular accident, is caused by an acute blockage of cerebral blood flow to an area of ​​the brain. With approximately half a million cases per year in the United States, 30% of which are fatal, stroke is thus the third leading cause of death in the United States. Eighty percent of these strokes are "ischemic," which results from an acute embolism (usually a blood clot or thrombus) in a brain artery and a reduction in blood flow. The remaining part is "hemorrhagic", which means that a large amount of blood flows into the brain organ due to the rupture of the cerebral artery, and then the blood flow is blocked due to the contraction of the local tissue, resulting in ischemia. [0003] Stroke usually occurs in individuals over the age of 65, and high blood pressure is the leading risk ...

AI Technical Summary

Problems solved by technology

However, insulin use is complicated by uncertainties about the neurotoxicity of hyperglycemia, the potential benefits of moderate glycemia, and the lethal potential of severe hypoglycemia